Company Description
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF).
It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial.
The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021.
Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
| Country | United States |
| Founded | 2019 |
| IPO Date | Feb 7, 2025 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 59 |
| CEO | Michael Cloonan |
Contact Details
Address: 21 Hickory Drive, Suite 500 Waltham, Massachusetts 02451 United States | |
| Phone | 617 819 2020 |
| Website | sionnatx.com |
Stock Details
| Ticker Symbol | SION |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 2036042 |
| CUSIP Number | 829401108 |
| ISIN Number | US8294011080 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Greg Hurlbut Ph.D. | Co-Founder and Senior Vice President of Discovery Research |
| Dr. Mark Munson Ph.D. | Co-founder and Senior Vice President of Medicinal Chemistry |
| Andy Chu | Vice President of Information and Technology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 21, 2026 | SCHEDULE 13D/A | Filing |
| Sep 17, 2026 | 144 | Filing |
| Sep 14, 2026 | 8-K | Current Report |
| Aug 10, 2026 | 8-K | Current Report |
| Aug 6, 2026 | 10-Q | Quarterly Report |
| Aug 6, 2026 | 8-K | Current Report |
| Jul 6, 2026 | 144 | Filing |
| Jun 18, 2026 | 8-K | Current Report |
| Jun 1, 2026 | 144/A | Filing |
| May 29, 2026 | 144 | Filing |